Pharmacokinetics of intravenous polymyxin B in critically ill patients. - Wikidata - awgldk - TriplyDB

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

http://www.wikidata.org/entity/Q44808038

about

Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 Hours Effective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin B In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore The Antibiotic Polymyxin B Impairs the Interactions between Shiga Toxins and Human Neutrophils.Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways.Colistin in the 21st century.Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.Colistin and polymyxin B: peas in a pod, or chalk and cheese?Screening and biological activities of pedopeptins, novel inhibitors of LPS produced by soil bacteria.In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.Host-dependent Induction of Transient Antibiotic Resistance: A Prelude to Treatment Failure.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods Structure-activity relationships for the binding of polymyxins with human α-1-acid glycoprotein Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol.Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Pharmacokinetics and renal disposition of polymyxin B in an animal model.Human oligopeptide transporter 2 (PEPT2) mediates cellular uptake of polymyxins.Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells.Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media.Polymyxins: wisdom does not always come with age.Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.Polymyxin B versus colistin: an update.Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Recent advances and perspectives in the design and development of polymyxins.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.Comprehensive Guidance for Antibiotic Dosing in Obese Adults.Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.

P2860

Q28391044-DB03ECB1-8A03-4C67-9FDC-7F9DCCBA55C8 Q28478261-768A18F2-A55E-402C-B5D0-79EC38E0E29C Q28740868-D5E0503E-13D8-471E-96A6-04055D603BA4 Q33428611-EE11A5A8-3C85-434D-8EC4-75372BDB32C7 Q33662378-C33A54E1-D04B-4EA1-A0F9-4330060E1CC4 Q33798324-ECB6E0BE-A3EA-4534-8912-FB57BC4C10A1 Q33847509-6DA44071-A375-481C-9330-6F9AE154BF37 Q34346283-7635E9FD-A78D-458C-B1A1-BA3BAC32DB54 Q35008357-8AE9169A-BC55-4BA4-ACDB-521FAFD8221C Q35054823-5D8D591A-8A27-4B7E-86D5-46EAA39E8567 Q35385713-D32DC5D4-8EEA-46BF-9E86-7AC15B1E7EAD Q35598359-89430B3C-742C-4D98-8C6F-C12D03F147B0 Q36089663-21ADB2B8-8B0C-4187-9260-A25CDBAF1F85 Q36106267-D5ECAFAD-676E-4867-9850-A097D291715E Q36158501-887C6FD9-A5FD-4CB6-8B33-34D01B6FBC87 Q36252997-82F7CBAA-C2B5-44C2-8275-39890883FD0D Q36255587-A09E9791-573E-4085-ACCA-B5976A5C59EE Q36335694-888B2C01-D714-4E23-9227-E84F2EABD23B Q36364194-F3B34D3C-475D-4E82-9545-45AC52552CF0 Q36455352-87598313-81CA-4B17-8B2C-F92072E8CC8F Q36571918-EC101BCD-DE4A-480B-849A-11AD2B3D0B54 Q36667079-D2471B29-EE09-41DF-AD56-68DECF7C326B Q36887819-52E652C2-4EFD-460C-BF52-1DCABFA5D007 Q37124019-8DED1F64-9FEF-461C-8A3D-03D79D3367C9 Q37165591-45CA87B0-1EEA-4003-823C-8F4266677B45 Q37263364-21EF5879-FDAA-4EC2-960F-2276690C7316 Q37360650-895D2125-0848-495F-B97E-F4A83560ABFF Q37656243-0FC5A725-DC8D-4148-9A4E-CF2B82DCBD2D Q37669021-FB2A50A9-1C86-46AA-9AB7-538B88164B04 Q38111213-FFA2F511-2854-406D-8CDC-7C6CD1083D01 Q38231648-3B67054B-2FD0-4D0E-A223-43BD26B74C15 Q38416932-88C2CDAE-A187-46A7-87CB-633CF423751D Q38613051-5C286753-5802-4192-9B5F-99CAFEEBB714 Q38755683-BA61EAA3-7629-44E6-92A2-975DE0A270AC Q38944862-F75B4385-D735-441C-8908-7FB85B1D7071 Q39190865-9ECD9771-90E8-46CE-928B-83C2576766C5 Q39333751-11855C24-8AD5-44B0-B45F-B3B87710009A Q40035349-06C47331-2B38-4202-BBD9-8741AA18655C Q40067964-1AB9A946-38C7-4B74-9F23-D5752A17079B Q40111993-18339A3A-5689-4270-8B65-721D3C9B4F5E

P2860

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

http://www.wikidata.org/entity/Q44808038

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

@en

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

@nl

type

label

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

@en

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

@nl

prefLabel

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

@en

Pharmacokinetics of intravenous polymyxin B in critically ill patients.

@nl

P1433

Q44808038-173C61AB-AEA0-4607-B7CD-ED272E35EC74

P1476

Q44808038-683BD31C-3EC9-4CE2-A7FD-EC9B1A7B56EF

P2093

Q44808038-0D446067-9E88-4BD9-82C7-ED9CB35224E3

Q44808038-16B33BB9-B671-4999-9BA5-C8412EE807F0

Q44808038-16F7D035-AB86-485B-A690-F2249616E3E9

Q44808038-5B193F27-8DF8-4E52-8B16-E7E131E5522E

Q44808038-630FF97C-7F8B-43DC-80C4-BDC2640BE81F

Q44808038-663AB807-ADB6-4435-A8B8-F2DA2942227F

Q44808038-E735A7D6-4402-44E6-985C-858B29D59118

P2860

Q44808038-021CBECF-FF35-4FF5-88F8-7C7F2C4308E0

Q44808038-09A35E69-9481-41B0-8513-16988EEE6443

Q44808038-12531372-BAAD-4C51-974B-580F614CF9ED

Q44808038-186BB40B-D9E7-4F74-9EB9-679BAA16EE56

Q44808038-34178318-3484-4984-A9A7-8DE157583F37

Q44808038-36B333F6-E106-4CDF-B8CB-F486F2500BBC

Q44808038-379DB6DD-3C78-42E4-892F-646D899E93DE

Q44808038-48DDF92C-6DAF-4705-8A97-CFEEF8936C90

Q44808038-5A9DEDE9-B0F3-4C99-82BC-83EC9DBDDFCE

Q44808038-7A1CC863-6678-44BF-B3DA-25C73CE4806B

P304

Q44808038-13F314D9-DCDA-409A-B8A9-4563BBE637D6

P31

Q44808038-612DB529-6A61-4318-A25E-3EEB2A81E39B

P356

Q44808038-F22F5027-C300-4828-9343-CB2433261B54

P407

Q44808038-14C99302-B0F9-4CC4-B94D-2622F95ABD02

P433

Q44808038-1F13EF98-39BF-46BB-AA96-DA07C3FF9FC8

P478

Q44808038-0B3C3314-11D3-4590-AEEC-83637A997F8E

P50

Q44808038-E8786865-D2A4-4BE2-95ED-249AE1FCE6DC

Q44808038-F4175B41-90A9-4F0A-964E-8A0351962E29

Q44808038-FB1B04E3-218F-4533-96B2-7E0256FD189B

P577

Q44808038-1689C02A-9E64-4E4C-AB12-F163D863DA7A

P5875

Q44808038-1849E528-FA43-43A1-BFFD-CBF28F8EA122

P698

Q44808038-75758152-F6F9-4648-A73D-DA02B27516BD

P356

P1433

Clinical Infectious Diseases

P1476

Pharmacokinetics of intravenous polymyxin B in critically ill patients

@en

P2093

Afonso L Barth

http://www.w3.org/2001/XMLSchema#string

Alexandre P Zavascki

http://www.w3.org/2001/XMLSchema#string

Fabiano Ramos

http://www.w3.org/2001/XMLSchema#string

Guoying Cao

http://www.w3.org/2001/XMLSchema#string

Larissa Lutz

http://www.w3.org/2001/XMLSchema#string

Luciano Z Goldani

http://www.w3.org/2001/XMLSchema#string

Silvana V Superti

http://www.w3.org/2001/XMLSchema#string

P2860

Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.

Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis.

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.

Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

The need for new antibiotics.

P304

1298-1304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/592577

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Márcio Manozzo Boniatti

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23304525

http://www.w3.org/2001/XMLSchema#string

P698

18840079

http://www.w3.org/2001/XMLSchema#string